Biotech Company, ENDV Should Be On Everyone's Watchlist

According to the Centers for Disease Control, Every Year 1.4 million People Suffer From a Traumatic Brain Injury in the United States

HENDERSON, NV / ACCESSWIRE / June 19, 2018 / ENDV officially announced the enrollment of their first patient in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company's senior secured Series C Preferred Stock financing.

With the recent advancement of companies who specialize in brain injuries and trauma advancing at a tremendous rate there is plenty of reason for optimism. There is the potential these treatments may offer a remedy to athletes in high impact sports like boxing, UFC, and the NFL.

These biotech companies are on the rise and should be on everyone's radar: Endonovo Therapeutics, Inc. (ENDV), Eleven Biotherapeutics, Inc (NASDAQ: EBIO)

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $13.18M, current share price: $0.04

Endonovo Therapeutics (ENDV) is a commercial-stage developer of non-invasive medical devices designed to deliver its proprietary Electroceuticalâ„¢ Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceuticalâ„¢ Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceuticalâ„¢ Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceuticalâ„¢ Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

Eleven Biotherapeutics, Inc (NASDAQ: EBIO)

Market Cap: $157.22M, current share price: $3.29

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixty thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators
Contact Person: Media Manager
Phone: 1-702-720-6310
Country: United States

SOURCE: ACR Communication, LLC

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.